Insulin-like growth factor 1 receptor polymorphism rs2229765 and circulating interleukin-6 level affect male longevity in a population-based prospective study (Treviso Longeva− TRELONG)

References

• Boyden SE, Kunkel LM. High-density genomewide linkage analysis of exceptional human longevity identifies multiple novel loci. PLoS ONE 2010;5:e12432.
   Google Scholar
• Jazwinski SM, Kim S, Dai J, Li L, Bi X, Jiang JC, Arnold J, et al.; Georgia Centenarian Study and the Louisiana Healthy Aging Study. HRAS1 and LASS1 with APOE are associated with human longevity and healthy aging. Aging Cell 2010;9:698–708.
   PubMed Web of Science ®Google Scholar
• Atzmon G, Barzilai N, Surks MI, Gabriely I. Genetic predisposition to elevated serum thyrotropin is associated with exceptional longevity. J Clin Endocrinol Metab 2009;94:4768–4775.
   PubMedGoogle Scholar
• Barzilai N, Gabriely I, Atzmon G, Suh Y, Rothenberg D, Bergman A. Genetic studies reveal the role of the endocrine and metabolic systems in aging. J Clin Endocrinol Metab 2010;95:4493–4500.
   Google Scholar
• McGue M, Vaupel JW, Holm N, Harvald B. Longevity is moderately heritable in a sample of Danish twins born 1870-1880. J Gerontol 1993;48:B237–B244.
   PubMedGoogle Scholar
• Perls T. Genetic and environmental influences on exceptional longevity and the AGE nomogram. Ann N Y Acad Sci 2002;959:1–13.
   Google Scholar
• Olsen A, Vantipalli MC, Lithgow GJ. Using Caenorhabditis elegans as a model for aging and age-related diseases. Ann N Y Acad Sci 2006;1067:120–128.
   PubMed Web of Science ®Google Scholar
• Kim SK. Common aging pathways in worms, flies, mice and humans. J Exp Biol 2007;210:1607–1612.
   Google Scholar
• Spanier B, Rubio-Aliaga I, Hu H, Daniel H. Altered signalling from germline to intestine pushes daf-2;pept-1 Caenorhabditis elegans into extreme longevity. Aging Cell 2010;9:636–646.
   Google Scholar
• Selman C, Lingard S, Choudhury AI, Batterham RL, Claret M, Clements M, Ramadani F, et al. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J 2008;22:807–818.
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Ilias I. Interleukin-6: a cytokine and/or a major modulator of the response to somatic stress. Ann N Y Acad Sci 2006;1088:373–381.
   PubMed Web of Science ®Google Scholar
• Cameron AR, Anton S, Melville L, Houston NP, Dayal S, McDougall GJ, Stewart D, Rena G. Black tea polyphenols mimic insulin/insulin-like growth factor-1 signalling to the longevity factor FOXO1a. Aging Cell 2008;7:69–77.
   Google Scholar
• Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J, Li H, Kenyon C. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 2003;424:277–283.
   PubMed Web of Science ®Google Scholar
• Pinkston-Gosse J, Kenyon C. DAF-16/FOXO targets genes that regulate tumor growth in Caenorhabditis elegans. Nat Genet 2007;39:1403–1409.
   PubMed Web of Science ®Google Scholar
• Salminen A, Kaarniranta K. Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal 2010;22:573–577.
   PubMed Web of Science ®Google Scholar
• Hall K, Hilding A, Thorén M. Determinants of circulating insulin-like growth factor-I. J Endocrinol Invest 1999;22:48–57.
   PubMed Web of Science ®Google Scholar
• Münzer T, Rosen CJ, Harman SM, Pabst KM, St Clair C, Sorkin JD, Blackman MR. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men. Am J Physiol Endocrinol Metab 2006;290:E1006–E1013.
   Web of Science ®Google Scholar
• Lanfranco F, Gianotti L, Giordano R, Pellegrino M, Maccario M, Arvat E. Ageing, growth hormone and physical performance. J Endocrinol Invest 2003;26:861–872.
   PubMedGoogle Scholar
• Bonafè M, Barbieri M, Marchegiani F, Olivieri F, Ragno E, Giampieri C, Mugianesi E, et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab 2003;88:3299–3304.
   PubMed Web of Science ®Google Scholar
• Ostan R, Bucci L, Capri M, Salvioli S, Scurti M, Pini E, Monti D, Franceschi C. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation 2008;15:224–240.
   PubMed Web of Science ®Google Scholar
• Van Bodegom D, May L, Meij HJ, Westendorp RG. Regulation of human life histories: the role of the inflammatory host response. Ann N Y Acad Sci 2007;1100:84–97.
   PubMed Web of Science ®Google Scholar
• Jylhä M, Paavilainen P, Lehtimäki T, Goebeler S, Karhunen PJ, Hervonen A, Hurme M. Interleukin-1 receptor antagonist, interleukin-6, and C-reactive protein as predictors of mortality in nonagenarians: the vitality 90+ study. J Gerontol A Biol Sci Med Sci 2007;62:1016–1021.
   Google Scholar
• Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369–1376.
   PubMed Web of Science ®Google Scholar
• Bonafè M, Olivieri F, Cavallone L, Giovagnetti S, Mayegiani F, Cardelli M, Pieri C, et al. A gender–dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001;31:2357–2361.
   PubMed Web of Science ®Google Scholar
• Capurso C, Solfrizzi V, D’Introno A, Colacicco AM, Capurso SA, Semeraro C, Capurso A, Panza F. Interleukin 6-174 G/C promoter gene polymorphism in centenarians: no evidence of association with human longevity or interaction with apolipoprotein E alleles. Exp Gerontol 2004;39:1109–1114.
   PubMed Web of Science ®Google Scholar
• Christiansen L, Bathum L, Andersen-Ranberg K, Jeune B, Christensen K. Modest implication of interleukin-6 promoter polymorphisms in longevity. Mech Ageing Dev 2004;125:391–395.
   PubMed Web of Science ®Google Scholar
• Hurme M, Lehtimäki T, Jylhä M, Karhunen PJ, Hervonen A. Interleukin-6 -174G/C polymorphism and longevity: a follow-up study. Mech Ageing Dev 2005;126:417–418.
   PubMed Web of Science ®Google Scholar
• Gruenewald TL, Seeman TE, Ryff CD, Karlamangla AS, Singer BH. Combinations of biomarkers predictive of later life mortality. Proc Natl Acad Sci USA 2006;103:14158–14163.
   PubMed Web of Science ®Google Scholar
• Gallucci M, Ongaro F, Bresolin F, Bernardi U, Salvato C, Minello A, Amici GP, et al. The Treviso Longeva (Trelong) study: a biomedical, demographic, economic and social investigation on people 70 years and over in a typical town of North-East of Italy. Arch Gerontol Geriatr 2007;44 Suppl 1:173–192.
   Google Scholar
• Albani D, Batelli S, Polito L, Vittori A, Pesaresi M, Gajo GB, De Angeli S, et al. A polymorphic variant of the insulin-like growth factor 1 (IGF-1) receptor correlates with male longevity in the Italian population: a genetic study and evaluation of circulating IGF-1 from the “Treviso Longeva (TRELONG)” study. BMC Geriatr 2009;21:9–19.
   Google Scholar
• Albani D, Batelli S, Polito L, Prato F, Pesaresi M, Gajo GB, De Angeli S, et al. Interleukin-6 plasma level increases with age in an Italian elderly population (“The Treviso Longeva”-Trelong-study) with a sex-specific contribution of rs1800795 polymorphism. Age (Dordr) 2009;31:155–162.
   Google Scholar
• Gallucci M, Amici GP, Ongaro F, Gajo GB, De Angeli S, Forloni GL, Albani D, et al. Associations of the plasma interleukin 6 (IL-6) levels with disability and mortality in the elderly in the Treviso Longeva (Trelong) study. Arch Gerontol Geriatr 2007;44 Suppl 1:193–198.
   Google Scholar
• Marsili M, Marsiglia D. Tavole di mortalità della popolazione italiana per provincia e regione di residenza. Anno 1998. Istituto Nazionale di Statistica (Istat), ed. Roma; Servizio Popolazione Istruzione Cultura [Italian] 2001.
   Google Scholar
• Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, Odijk H, et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 2006;444:1038–1043.
   PubMed Web of Science ®Google Scholar
• Mariño G, Ugalde AP, Fernández AF, Osorio FG, Fueyo A, Freije JM, López-Otín C. Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. Proc Natl Acad Sci USA 2010;107:16268–16273.
   Google Scholar
• Major JM, Laughlin GA, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Insulin-like growth factor-I and cancer mortality in older men. J Clin Endocrinol Metab 2010;95:1054–1059.
   PubMed Web of Science ®Google Scholar
• Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LØ. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol 2009;160:25–31.
   PubMed Web of Science ®Google Scholar
• Maggio M, Lauretani F, Ceda GP, Bandinelli S, Ling SM, Metter EJ, Artoni A, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007;167:2249–2254.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Bonafè M. Centenarians as a model for healthy aging. Biochem Soc Trans 2003;31:457–461.
   PubMed Web of Science ®Google Scholar
• Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 2003;88:2019–2025.
   PubMed Web of Science ®Google Scholar